Infectious Diseases

During the era of infectious diseases (from 1870 to 1945), the advent of antimicrobials including therapeutics and prophylactics by mankind could attain control on the then severe mortality rates. However, the disease causative agents proved to be more challenging by emerging as resistant to treatment or to prophylaxis or to contain. Till date, there are several emerging infectious diseases for which successful disease management strategies have not been underplayed to prevent new outbreaks, expansion of the disease endemicity and obviously a prevention mechanism.

Pentavalent is presently focusing on developing a vaccine solution for the deadly infectious disease “Influenza” and an innovative technology to diagnose “Tuberculosis”.



Flu is an infectious zoonotic disease of pandemic and epidemic concern worldwide since the human race has witnessed its impact on avian contemporaries, swine and mammals including man himself since 16th century. Till date, the infection causative influenza virus has caused four pandemics worldwide including Spanish flu in 1918, Asian flu in 1957, Hong Kong influenza in 1968 and swine flu in 2009. Additionally, the virus is very often causing epidemics in diverse locations and seasons worldwide.

Development and production of novel, promising, influenza vaccines that confer cross-protection against broad range of influenza strains among susceptible populations is an important component of influenza response.

A Universal Influenza Vaccine

Pentavalent is working on a live attenuated universal influenza vaccine (mimicking wild virus) with potential to confer long-lasting cross protection against pan influenza strains across type A and B. It has the potential of generating herd immunity to reduce the morbidity and mortality rate of both pandemic and seasonal influenza epidemics.


Universal access to rapid and accurate laboratory diagnostics is necessary to control tuberculosis. Emergence of multidrug resistant and extensive drug resistant TB has devastating effects on the disease management. China and India carry approximately 54% of the global burden. The largely untapped group of tuberculosis infected patients falls under poor sectors in poor and developing countries.

Congested fashion of living, failing to get diagnosed and incomplete treatment enables spread and emergence of drug-resistance cases. Currently followed diagnosis and treatment methods are time consuming and unaffordable. Accurate drug resistance profiling is critical in TB treatment.

Tuberculosis Treatment Decision Support

Pentavalent has come up with a novel and innovative enzymatic and nucleic acid combined diagnostic solution that supports a doctor to make a treatment decision in an affordable and rapid fashion.

The technology is for simultaneous detection of tuberculosis and multiple point mutations associated with drug resistance gene(s) to provide patient specific treatment decision as a point of care assay for patients suffering with TB infections.


Single-Nucleotide Polymorphism Genotyping Platforms

Genomic testing has revolutionized the diagnostics field in both infectious diseases and genetic disorders verticals. This approach supports a doctor to make customized treatment decision.

The innovative enzymatic and nucleic acid combined diagnostic solution developed at Pentavalent is being exploited for development of genomic testing tools for diagnosis of an array of healthcare issues including tuberculosis, HIV, HBV, HCV, sexually transmitted diseases, cancers, diabetes and other genetic disorders.


“To invent and investigate indigenous medical management of diseases and infections and to share the benefits of our findings with the BioWorld.”

Funding Support

Recognitions and Awards

Collaborators and Partners

Contact Us

Corporate Office and R&D Unit
Pentavalent Bio Sciences Pvt Ltd
Institute of Bioinformatics and Applied Biotechnology
Biotech Park, Electronic City, Phase I
Bangalore – 560 100